National Center of Neurology and Psychiatry and Nippon Shinyaku announce positive results for a Phase I/II study evaluating the efficacy and safety of their exon 44 skipping drug (NS-089/NCNP-02) Results […]
In 2015, CureDuchenne supplied early funding to Capricor Therapeutics in support of a novel, first-in-class therapy to improve cardiac function in people with Duchenne muscular dystrophy. Duchenne can cause debilitating […]
In this webinar, the NS Pharma team presents updates for the Duchenne community: Access programs for Viltepso, which is suitable for individuals with Duchenne who are amenable to exon 53 […]
